Please login to the form below

Not currently logged in

Sanofi Pasteur to acquire US biotech

Sanofi Pasteur has announced it is to acquire the US biotech company VaxDesign in a deal worth $60m

Sanofi Pasteur has announced it is to acquire the US biotech company VaxDesign in a deal worth $60m.

Sanofi Pasteur, the vaccines division of sanofi-aventis, will make an upfront payment of $55m upon closing the transaction, with the completion of certain development stages increasing the deal by $5m.

Florida-based VaxDesign is the developer of the Modular IMmune In-vitro Construct (MIMIC) technology – a novel system to combine immunology with engineering to aid research into biological problems.

MIMIC uses data generated in a surrogate human immune system to help determine the selection of optimal product candidates. This surrogate system is intended to be used instead of animal models before studies progress to human clinical trials.

"MIMIC is the most-advanced platform in the field,” said Dr Michel DeWilde, senior vice president, R&D, Sanofi Pasteur. "With this novel model for understanding mechanisms of action, the probability of clinical success increases and the time to market should decrease."

He continued: "MIMIC successfully reproduced our own clinical data and is adaptable for the evaluation of multiple diseases and corresponding patient populations. This platform will provide a significant competitive advantage in the development of vaccines."

28th September 2010


Featured jobs

Subscribe to our email news alerts


Add my company
Research Partnership

We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the...

Latest intelligence

figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...